These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 6301776)

  • 1. Laboratory evaluation of cefmenoxime: a new cephalosporin. In vitro and in vivo antibacterial activities and pharmacokinetic properties.
    Matsumoto K; Nagatake T; Uzuka Y; Harada T; Rikitomi N
    Chemotherapy; 1983; 29(2):80-8. PubMed ID: 6301776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The antibacterial activity of new cephem antibiotics against clinical isolates. A comparison of the antibacterial activity of cefotaxime with 6 other antibiotics].
    Miwatani T; Takeda Y; Kotera K; Nishimura T; Takashima T; Hiromatsu K; Tabuki K; Fujimoto S; Kamiki T; Yoshizaki E; Yabuuchi E; Shimizu Y; Matsunaga K; Yamanaka K; Furuta I; Iimori M; Kodama J; Tanaka M; Maejima K; Nukina M; Takashima E; Takahashi M; Harikane O; Masutani T
    Jpn J Antibiot; 1983 Feb; 36(2):260-76. PubMed ID: 6304368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of cefotiam, cefmenoxime, and ceftriaxone in experimental endocarditis and correlation with pharmacokinetics and in vitro efficacy.
    Pangon B; Joly V; Vallois JM; Abel L; Buré A; Brion N; Contrepois A; Carbon C
    Antimicrob Agents Chemother; 1987 Apr; 31(4):518-22. PubMed ID: 3300530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefmenoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Campoli-Richards DM; Todd PA
    Drugs; 1987 Aug; 34(2):188-221. PubMed ID: 3304966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1992)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
    Jpn J Antibiot; 1996 Jan; 49(1):34-70. PubMed ID: 8851305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Laboratory and clinical studies of cefmenoxime in pediatric infections].
    Miyachi Y; Nakashima T; Aso K; Nishikawa K; Ogawa A; Yafuso M; Kuno K
    Jpn J Antibiot; 1982 Oct; 35(10):2459-67. PubMed ID: 6306297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity.
    Watanabe N; Katsu K; Moriyama M; Kitoh K
    Antimicrob Agents Chemother; 1988 May; 32(5):693-701. PubMed ID: 3134847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefmenoxime: in vitro activity.
    Stamm JM
    Am J Med; 1984 Dec; 77(6A):1-3. PubMed ID: 6097114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical laboratory approach for estimating effective administrative dosage of cefmenoxime. Observation on the MICS and cefmenoxime disc susceptibility test].
    Uete T; Matsuo K
    Jpn J Antibiot; 1984 May; 37(5):791-801. PubMed ID: 6090721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the diffusion of cefotiam in the bronchial secretions.
    Bergogne-Berezin E; Berthelot G; Kafe H
    Chemotherapy; 1982; 28(5):327-33. PubMed ID: 6291865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity and beta-lactamase stability of cefmenoxime.
    Neu HC; Labthavikul P
    Antimicrob Agents Chemother; 1982 Aug; 22(2):316-22. PubMed ID: 6100427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Studies on penetration of antibiotics to gallbladder tissue and bile, its surgical significance. Mainly with cefmenoxime].
    Tsuburaya H; Watanabe I; Endo S; Oikawa M
    Jpn J Antibiot; 1985 Jan; 38(1):31-40. PubMed ID: 3857360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibacterial activities of new cephems against clinically isolated organisms (author's transl)].
    Okada K; Kawamura N; Ohkoshi M; Satake Y; Kawakita J
    Jpn J Antibiot; 1982 Apr; 35(4):1009-21. PubMed ID: 6285019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1995)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kawaguchi H; Shimizu Y; Matsumiya H; Saito A; Terai T; Inoue H; Nakadate T; Ito C; Yosida T; Tanno Y; Ohno I; Nishioka K; Arakawa M; Igarashi K; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Touyama M
    Jpn J Antibiot; 1997 May; 50(5):421-59. PubMed ID: 9212366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Serum levels and sputum levels of cefmenoxime in respiratory tract infections].
    Matsumoto Y; Ninomaru S; Koshobu T; Ishikawa J; Nakatani S; Sasaki T
    Jpn J Antibiot; 1985 Jun; 38(6):1638-42. PubMed ID: 3862881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of the therapeutic effect of cephalosporins in experimental endocarditis by altering their pharmacokinetics with diclofenac.
    Joly V; Pangon B; Brion N; Vallois JM; Carbon C
    J Pharmacol Exp Ther; 1988 Aug; 246(2):695-700. PubMed ID: 3042958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1993)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
    Jpn J Antibiot; 1996 Feb; 49(2):107-43. PubMed ID: 8721076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro bacteriostatic activity of cefmenoxime (SCE 1365), cefotaxime and moxalactam].
    Husson MO; Bryskier A; Izard D; Leclerc H
    Pathol Biol (Paris); 1983 May; 31(5):347-50. PubMed ID: 6312395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.